Sionna Therapeutics releases Phase 2a SION-719, Phase 1 SION-451 dual-combination data presentation
SION•Cash position and next steps
Cash and cash equivalents were about $268 million as of 2Q26; capital-preservation actions are planned while next steps are evaluated.
Phase 2a SION-719 results missed key endpoint
Sionna Therapeutics released clinical topline results for its NBD1 stabilizer programs SION-719 Phase 2a in cystic fibrosis.
- PreciSION CF missed the key activity endpoint, showing a -1 mmol/L placebo-adjusted sweat chloride change when SION-719 was added to Trikafta.
- Development of SION-719 as an add-on to standard of care will not advance.
Phase 1 SION-451 dual-combination study met safety and PK objectives
SION-451 dual-combination Phase 1 met predefined safety, tolerability, and pharmacokinetic objectives; the preferred regimen was SION-451 BID with SION-2222 QD.
